Primary prophylaxis was associated with lower arthropathy in Colombian men with haemophilia B: A longitudinal analysis (2015‐2019)

Introduction The risk of chronic haemophilic arthropathy (CHA) is related to severity. Evidence suggests that primary prophylaxis (PPr) could reduce CHA incidence and its impact on quality of life. Aim To evaluate the association between PPr and CHA in Colombian males with haemophilia B (HB) during...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2020-11, Vol.26 (6), p.e282-e290
Main Authors: Hernández Vargas, Juliana Alexandra, Linares, Adriana, Solano, María Helena, Valbuena, Ana María, Acuña, Lizbeth
Format: Article
Language:English
Subjects:
Diagnosis
Factor IX deficiency
haemophilia B
haemophilic arthropathy
Hemophilia
men
Prophylaxis
Quality of life
registries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction The risk of chronic haemophilic arthropathy (CHA) is related to severity. Evidence suggests that primary prophylaxis (PPr) could reduce CHA incidence and its impact on quality of life. Aim To evaluate the association between PPr and CHA in Colombian males with haemophilia B (HB) during 2015 to 2019. Methods A panel‐time analysis was performed with data provided by the National Health System to update a nationwide open cohort of people with congenital coagulopathies. The association was evaluated in a logistic random‐effect regression model (LRERM), adjusted by age at diagnosis, prophylaxis dose and frequency, severity, haemarthrosis and high‐titre inhibitors. Results During 2015‐2019, a total of 362 men with HB and treated with either, primary, secondary or tertiary prophylaxis were identified. At baseline, CHA prevalence in the cohort was 36.84% (n = 133), median age was 19.0 years (IQR: 10.0‐27.0), and median age at diagnosis was 1.0 year (IQR: 0.0‐4.0). PPr was prescribed in 37.85% (n = 137), and median dose (IU/Kg/dose) was almost the same for primary vs. secondary/tertiary prophylaxis. Patients in PPr had a lower frequency of severe HB, CHA, haemarthrosis, infectious complications and high‐titre inhibitors than those in secondary or tertiary prophylaxis (STPr). In the LRERM, PPr was associated with a significant reduction of 89.70% in the odds of CHA (aOR = 0.103, IC 95%: 0.040, 0.270; P 
ISSN:1351-8216
1365-2516
DOI:10.1111/hae.14136